Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207826 | 0.76 | MEN1 (0.37) | MCL1L3MBTL1ALDH1A1MAPTCYP3A4 | |
| SCHEMBL6081252 | 0.73 | MCL1 (0.34) | MCL1ALDH1A1MAPT | |
| SCHEMBL6081113 | 0.72 | CTSS (0.38) | MCL1 | |
| SCHEMBL6081756 | 0.69 | ALDH1A1 (0.42) | MCL1ALDH1A1MAPTCYP3A4 | |
| SCHEMBL11506006 | 0.67 | ALDH1A1 (0.32) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL2947816 | 0.62 | — | — | |
| SCHEMBL9638607 | 0.62 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL11439214 | 0.61 | MCL1 (0.52) | MCL1ALDH1A1CYP3A4 | |
| SCHEMBL6080111 | 0.60 | MEN1 (0.36) | MCL1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL9789288 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MCL1 3498/4885L3MBTL1 1128/4885ALDH1A1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.